<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614315</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-07-001</org_study_id>
    <nct_id>NCT00614315</nct_id>
  </id_info>
  <brief_title>FLAIR™ Delivery System Study</brief_title>
  <acronym>FLAIR DS</acronym>
  <official_title>A Prospective Observational Study of the FLAIR™ Endovascular Stent Graft Optimized Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the performance of the Optimized FLAIR™
      Delivery System.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success for Delivery</measure>
    <time_frame>Measured at the time of implantation (Day 0)</time_frame>
    <description>defined as deployment of the implant to the intended location, assessed at the time of the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Device/Procedure-related Adverse Events(Safety of Delivery)</measure>
    <time_frame>Index Procedure to 30 days</time_frame>
    <description>Device/Procedure-related adverse events from the index procedure through 30 days post procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Constriction, Pathologic</condition>
  <arm_group>
    <arm_group_label>FLAIR Endovascular Stent Graft and Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLAIR™ Endovascular Stent Graft</intervention_name>
    <description>The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).</description>
    <arm_group_label>FLAIR Endovascular Stent Graft and Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is either a male or non-pregnant female ≥ 18 years old.

          -  The subject has been properly informed about the study per IRB requirements, and has
             signed and dated the IRB-approved ICF.

          -  The subject is willing to comply with the protocol requirements and can be contacted
             by telephone.

          -  The subject has a synthetic AV access graft located in an arm that has been implanted
             for &gt; 30 days and has undergone at least one successful dialysis session prior to the
             index procedure.

          -  Angiographic evidence indicates that the subject has a stenosis of &gt;50% located at the
             graft-vein anastomosis of the subject's synthetic AV access graft.

          -  The target lesion is estimated to be ≤ 7 cm in length by angiography prior to
             performance of any interventional procedures.

          -  The entire target lesion is located within 7 cm of the graft-vein anastomosis, as
             verified by angiography, such that approximately 1 cm of the FLAIR™ Endovascular Stent
             Graft will extend into non-diseased vein and approximately 1 cm but no more than 2 cm
             of the FLAIR™ Endovascular Stent Graft will extend into non-diseased AV graft.

          -  Graft diameter at the deployment site is between 5 mm and 8 mm, as verified by
             angiography.

          -  Full expansion of an appropriately sized angioplasty balloon, in the operator's
             judgment, can be achieved during primary angioplasty.

        Exclusion Criteria:

          -  The subject has a life expectancy of &lt; 6 months.

          -  The presence of a previously placed stent and/or stent graft located in the treatment
             area. The treatment area is defined as the entire target lesion and 1 cm of landing
             zone into both non-diseased AV graft and non-diseased vein.

          -  The subject has an infected AV access graft or other infection.

          -  The location of the target lesion would require that the FLAIR™ Endovascular Stent
             Graft be deployed fully across the elbow joint.

          -  The location of the target lesion would require that the FLAIR™ Endovascular Stent
             Graft cross an angle (between the outflow vein and synthetic AV access graft) that is
             &gt; 90 degrees.

          -  The subject has an uncorrected blood coagulation disorder.

          -  The subject has a known allergy or sensitivity to contrast media which cannot be
             adequately pre-medicated.

          -  Subject is currently enrolled or scheduled to be enrolled in other investigations that
             conflict with follow-up testing or confounds data in this trial.

          -  The subject has a known hypersensitivity to nickel-titanium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Rosenblatt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Connecticut Image Guided Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Image Guided Surgery</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>February 20, 2009</results_first_submitted>
  <results_first_submitted_qc>September 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2010</results_first_posted>
  <last_update_submitted>January 14, 2017</last_update_submitted>
  <last_update_submitted_qc>January 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FLAIR Endovascular Stent Graft</title>
          <description>Patients treated with the FLAIR Endovascular Stent Graft</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FLAIR Endovascular Stent Graft</title>
          <description>Patients treated with the FLAIR Endovascular Stent Graft</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Success for Delivery</title>
        <description>defined as deployment of the implant to the intended location, assessed at the time of the index procedure.</description>
        <time_frame>Measured at the time of implantation (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR Endovascular Stent Graft</title>
            <description>Patients treated with the FLAIR Endovascular Stent Graft</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success for Delivery</title>
          <description>defined as deployment of the implant to the intended location, assessed at the time of the index procedure.</description>
          <units>Percentage of successful implantations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Device/Procedure-related Adverse Events(Safety of Delivery)</title>
        <description>Device/Procedure-related adverse events from the index procedure through 30 days post procedure</description>
        <time_frame>Index Procedure to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR Endovascular Stent Graft</title>
            <description>Patients treated with the FLAIR Endovascular Stent Graft</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Device/Procedure-related Adverse Events(Safety of Delivery)</title>
          <description>Device/Procedure-related adverse events from the index procedure through 30 days post procedure</description>
          <units>Number of Device/Procedure events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days post implantation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FLAIR Endovascular Stent Graft</title>
          <description>Patients treated with the FLAIR Endovascular Stent Graft</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis of Access Circuit</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Reviere, Director, Clinical Affairs</name_or_title>
      <organization>Bard Peripheral Vascular, Inc.</organization>
      <phone>480-303-2644</phone>
      <email>John.Reviere@crbard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

